
Lyell Immunopharma, Inc.: updates and filings
Price
$13.80
November 20, 2026Market cap $339M
What Ploutos Investor adds for Lyell Immunopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Shelf registration for future offeringsFormS-3
- Nov 10, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operationsForm8-K
- Nov 4, 2026Unregistered sale of sharesForm8-K
- Sep 10, 2026Other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jul 21, 2026FilingFormEFFECT
- Jul 17, 2026Correspondence with the SECFormCORRESP
- Jul 16, 2026Letter from the SECFormUPLOAD
- Jul 13, 2026Shelf registration for future offeringsFormS-3
- Jun 18, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 15, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 11, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Results of operationsForm8-K
- Apr 24, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 24, 2026Additional annual meeting materialFormDEFA14A
- Apr 24, 2026Annual meeting proxy statementFormDEF 14A
- Apr 21, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 14, 2026FilingFormEFFECT
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | S-3 | Shelf registration for future offerings | Document |
| Nov 10, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Nov 4, 2026 | 8-K | Unregistered sale of shares | Document |
| Sep 10, 2026 | 8-K | Other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jul 21, 2026 | EFFECT | Filing | Document |
| Jul 17, 2026 | CORRESP | Correspondence with the SEC | Document |
| Jul 16, 2026 | UPLOAD | Letter from the SEC | Document |
| Jul 13, 2026 | S-3 | Shelf registration for future offerings | Document |
| Jun 18, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 15, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 11, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| Apr 24, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 24, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 24, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 21, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 14, 2026 | EFFECT | Filing | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 20, 2020.
The full analysis
What do Lyell Immunopharma's filings show?
The filings are where every one of Lyell Immunopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.